| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 21.2MM | +9% |
| Gross Profit | 12.9MM | +8% |
| Cost Of Revenue | 8.3MM | +10% |
| Operating Income | -168K | -85% |
| Operating Expenses | 13.1MM | -0% |
| Net Income | 114K | -112% |
| R&D | 1.2MM | -7% |
| G&A | 5.4MM | -7% |
| Marketing | 6.5MM | +8% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Key Insights The projected fair value for ChromaDex is US$6.63 based on 2 Stage Free Cash Flow to Equity ChromaDex's...
LOS ANGELES, April 30, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces an ingredient partnership with Solgar®, a Nestlé Health Science brand. Solgar’s inaugural NAD+ supplement, Solgar Cellular Nutrition Cellular Energy, features ChromaDex’s patented nicotinamide riboside (NR) ingredient, NIAGEN® to support NAD+ levels for cellular health. This product marks a significant milestone in the health and welln
LOS ANGELES, April 25, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen®, is now available at The Vitamin Shoppe retail locations nationwide and online at www.vitaminshoppe.com. This retail expansion adds Tru Niagen to the shelves of 700 locations of The Vitamin Shoppe and Super Supplements, enhancing consumer access to the number one healthy-aging NAD+ sup
LOS ANGELES, April 24, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
LOS ANGELES, April 23, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut. As one of the fastest-growing retailers in the United States, Sprouts Farmers Market now offers Tru Niagen to its health-conscious consumers i
ChromaDex Corporation ( NASDAQ:CDXC ), might not be a large cap stock, but it led the NASDAQCM gainers with a...
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN
ChromaDex ( NASDAQ:CDXC ) Full Year 2023 Results Key Financial Results Revenue: US$83.6m (up 16% from FY 2022). Net...
Net Sales Rise to $83.6 Million with a Notable Gross Margin Improvement